Navigation Links
OxThera startar klinisk studie inom Primär Hyperoxaluri
Date:1/8/2014

STOCKHOLM, January 8, 2014 /PRNewswire/ --

OxThera AB, ett Stockholmsbaserat privat biofarmaceutiskt bolag, meddelar idag att det har startat en klinisk studie inom Primär Hyperoxaluri.  Offentliggörandet stärker ytterligare företagets position som ledare i att utveckla terapier för behandling av hyperoxaluri, en svår sjukdom som leder till njurskador och njurkollaps, om den inte behandlas.

"Vi är mycket glada att meddela att vi har startat vår konfirmerande kliniska studie inom Primär Hyperoxaluri", säger Elisabeth Lindner, VD för OxThera. "Vi är övertygade om att vår nya Oxabact® -produkt har potential att hjälpa patienter med denna svåra sjukdom", fortsätter Elisabeth Lindner.

Den placebokontrollerade studien, OC5-DB-01, utförs på 7 kliniker i tre länder och kommer att inkludera totalt 24 patienter. Resultatet väntas efter sommaren. Oxabact® är en oral produkt som utgörs av högkoncentrerade frystorkade levande bakterier (Oxalobacter formigenes), som administreras i kapslar. Kapslarna är designade för att leverera produkten i tunntarmen, där den så kallade enteriska elimineringen av oxalat initieras. En komplett utvecklingsplan för behandling av patienter som lider av Primär Hyperoxaluri med Oxabact®, har implementerats.

Primär Hyperoxaluri (PH) är en sällsynt autosomal recessiv sjukdom som leder till markant höjda nivåer av endogent oxalat i plasma och urin. Höga nivåer av oxalat ger njurskador och förkalkning av njurarna. Om sjukdomen inte behandlas, kan den orsaka njurkollaps och prematur död. Det finns idag ett stort behov av en fungerande medicinsk behandling för PH. I nuläget är d
'/>"/>

SOURCE OxThera AB
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. OxThera coordonne le projet Elimox du 7e PC - 2,19 millions EUR dédiés au développement dun médicament pour traiter lhyperoxalurie
2. OxThera stärker patentportfölj för särläkemedel - Primär hyperoxaluri
3. OxThera stärkt sein Patentportfolio für primäre Hyperoxalurie, eine seltene Krankheit
4. OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria
5. RNL BIO Co. Ltd. lämnar in IND-ansökan om att påbörja klinisk fas II-prövning av RNL-JointStem för artros i USA
6. RNL BIO har anmält en fas II/III klinisk prövning till KFDA för en behandling av cerebral pares med autologa stamceller framställda från fettvävnad
7. ideaPoint Inc. präsentiert Multi-Sponsor-Portal für Forscheranfragen an fünf globale Studiensponsoren bezüglich Zugang zu Daten aus klinischen Studien
8. CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
9. Berg startet bisher erste klinische Stratified-Medicine-Studie zur Untersuchung des Krebsstoffwechsels solider Tumoren
10. Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
11. Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015  Legendary actor and director Danny ... PBAFacts campaign designed to educate and encourage patients with ... Pseudobulbar Affect (PBA) and to speak with their physician. ... has the ability to cry and laugh on cue ... experienced by people living with PBA episodes. ...
(Date:5/1/2015)... , May 1, 2015 Semler Scientific, Inc. ... company that develops, manufactures and markets products that assist ... today reported financial results for the first quarter ended ... quarter of 2015, Semler reported continued progress with year ... quarter revenue growth of 14%," said Doug Murphy-Chutorian ...
(Date:5/1/2015)... RUTHERFORD, N.J., May 1, 2015 Cambrex Corporation (NYSE: ... March 31, 2015. Highlights , ... and increased 27% excluding foreign currency impact, driven by Innovator ... million from $8.4 million in the first quarter of 2014. ... versus $0.04 in the first quarter last year and Adjusted ...
Breaking Medicine Technology:Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 2Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 3Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11
... the American Diabetes ... Association 68th Scientific Sessions, SAN FRANCISCO, June 7 ... today at the American Diabetes,Association (ADA) 68th Scientific Sessions by ... shown to be a highly,selective inhibitor of dipeptidyl peptidase-4 (DPP-4), ...
... SAN FRANCISCO, California, June 6 , - ... results from the world,s largest ever study of ... using modified release,gliclazide and other drugs as required, ... particular, intensive treatment reduces,the risk of kidney disease ...
Cached Medicine Technology:Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies 2Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies 3Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies 4The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications 2
(Date:5/1/2015)... May 01, 2015 Royal River Natural ... Maine, reports on a new study that found two ... swelling and improved physical function as well as standard ... osteoarthritis of the knee. , The report is part ... for Well Being® ,” which Royal River Natural Foods ...
(Date:5/1/2015)... It’s raining bills on Capitol Hill with members in both ... for telemedicine. , “Such action is unprecedented in ... said Jonathan Linkous, CEO of the American Telemedicine Association (ATA). ... embrace the use of telecommunications in the delivery of care. ... to improve quality, access, equity and affordability of healthcare.”, ...
(Date:5/1/2015)... The fields of genetics and genomics, ... of genes with one another and the environment, is ... , LabRoots, the premier producer of interactive virtual events ... host its annual conference spotlighting the recent advances in ... and Genomics 2015 , a two-day event presented entirely ...
(Date:5/1/2015)... 01, 2015 As the sale of ... 18-month anniversary, many people in the industry are looking ... According the latest annual report by the ArcView ... in 2014, and reached nearly $3 billion in combined ... affair with cannabis, combined with the ongoing economic recovery, ...
(Date:5/1/2015)... VA (PRWEB) May 01, 2015 On May ... Mexican celebration of Cinco de Mayo with a twist. ... of two 12 ounce or one 24 ounce frozen yogurt ... de Mayo celebration originated in 1862 in commemoration of a ... in Mexico and the United States, but events are also ...
Breaking Medicine News(10 mins):Health News:New Study Finds Nutrients Ease Arthritis Pain, Retailer Reports 2Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 3Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 3Health News:sweetFrog to Celebrate Cinco de Mayo with a Yogurt Twist 2
... Rebuilding Revenue Base While Stabilizing Costs--, TSX ... - Vancouver, BC, Canada - Neovasc Inc. (TSXV: NVC), today ... 2009. , "The first quarter continued to show financial effects ... on our most promising growth areas," said Alexei Marko, chief ...
... for Recently Introduced MicroRNA-based Diagnostics Also Unveiled , ... a specialty pharmaceutical and diagnostic company, presented an overview ... American Society of Clinical Oncology (ASCO) Annual Meeting in ... of Receptor Tyrosine Kinases (RTK) Activation in Circulating Tumor ...
... PITTSBURGH, June 1 Since one child in 20 will have ... many young people will experience a Father,s Day without dad on ... to help ease the pain at this time, the Highmark Caring ... programs and services as well as online tools at no cost. ...
... A panoramic downtown Milwaukee view, lush greenery ... rooftop healing garden at Aurora St. Luke,s Medical ... awaiting guests at the newly opened Vince Lombardi ... Morland Hamilton Healing Conservatory. , , (Logo: ...
... ... based on scientific evidence, not marketing muscle or claims. CX3, Max Muscle Sports ... , ... (PRWEB) June 1, 2009 -- Creatine is perhaps one of the most widely used ...
... Contact an SSDI representation ... for initial applications will jump by 20 percent this year , ... Belleville, IL (Vocus) June 1, 2009 -- The Social Security Disability Insurance ... the next couple of years. This will make it even more important for people to find ...
Cached Medicine News:Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 2Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 3Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 4Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 5Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 6Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 7Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 8Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 9Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 10Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 11Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 2Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 3Health News:Easing the Pain of Father's Day Without Dad, Highmark Caring Place Helps Children Cope With the Death of a Parent 2Health News:Easing the Pain of Father's Day Without Dad, Highmark Caring Place Helps Children Cope With the Death of a Parent 3Health News:Aurora St. Luke's Dedicates Rooftop Healing Garden and Conservatory 2Health News:Aurora St. Luke's Dedicates Rooftop Healing Garden and Conservatory 3Health News:Max Muscle Sports Nutrition Releases The Truth About Creatine 2Health News:Max Muscle Sports Nutrition Releases The Truth About Creatine 3Health News:Max Muscle Sports Nutrition Releases The Truth About Creatine 4Health News:Social Security Disability Backlog Worsens, So Make Sure You Qualify Before You Apply 2Health News:Social Security Disability Backlog Worsens, So Make Sure You Qualify Before You Apply 3Health News:Social Security Disability Backlog Worsens, So Make Sure You Qualify Before You Apply 4Health News:Social Security Disability Backlog Worsens, So Make Sure You Qualify Before You Apply 5
...
...
...
... employs titanium alloy plasma spray porous ... surface. Biomet's ArCom processed polyethylene is ... bearing material. The Maxim Knee System's ... tibial components offer excellent sizing options ...
Medicine Products: